Patritumab Deruxtecan | m-entrepreneurship.com

Product Name :
Patritumab Deruxtecan

Search keywords :
Patritumab

drugId :
null

Target Vo:
Receptor tyrosine-protein kinase erbB-3

Target Vo Short Name :
HER3

Moa_Name:
Receptor tyrosine-protein kinase erbB-3 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Daiichi Sankyo Co Ltd

Active Company_Name :
Baxter Oncology Gmbh

Active Indication_Name:
Carcinoma, Non-Small-Cell Lung

In Active Indication_Name:
Colorectal Neoplasms

Termination Status :

China Termination Status :

Highest Status:
NDA/BLA

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Cleaved-Caspase 8 Antibody
SIRT1 Antibody
NMDAR2A Antibody: NMDAR2A Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 165 kDa, targeting to NMDAR2A. It can be used for WB,IHC-P,IF assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts